The human FcγRII (CD32) family of leukocyte FCR in health and disease

Frontiers in Immunology

Volumn 10, Issue MAR, 2019, Pages

  Anania, Jessica C ^a,b   Chenoweth, Alicia M ^a,b   Wines, Bruce D ^a,b,c   MarkHogarth, P ^a,b,c  

^a BURNET INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Autoimmunity; Cancer; Fc receptor; Fc R; Infection; Inflammation; MAb therapeutics

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 3; INTERLEUKIN 6; TUMOR NECROSIS FACTOR; FC RECEPTOR; MONOCLONAL ANTIBODY;

AMINO ACID SEQUENCE; ANTIBIOTIC SENSITIVITY; ANTIRETROVIRAL THERAPY; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CELL ACTIVATION; CELL AGGREGATION; CELL INTERACTION; CHEMICAL STRUCTURE; COPY NUMBER VARIATION; CYTOKINE RELEASE; DNA POLYMORPHISM; GENE EXPRESSION; GENE REPLACEMENT THERAPY; GENE SEQUENCE; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; NEPHRITIS; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; REVIEW; RISK FACTOR; RNA SPLICING; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; VIRUS REPLICATION; ANIMAL; IMMUNOLOGY; LEUKOCYTE;

ANIMALS; ANTIBODIES, MONOCLONAL; AUTOIMMUNITY; HUMANS; LEUKOCYTES; RECEPTORS, IGG;

EID: 85064200634     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2019.00464     Document Type: Review

References (195)

1. Hogarth PM. Fc receptors are major mediators of antibody based inflammation in autoimmunity. Curr Opin Immunol. (2002) 14:798-802. doi: 10.1016/S0952-7915(02)00409-0
2. Hogarth PM, Pietersz GA. Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond. Nat Rev Drug Discov. (2012) 11:311-31. doi: 10.1038/nrd2909
3. Qiu WQ, De Bruin D, Brownstein BH, Pearse R, Ravetch JV. Orgaization of the human and mouse low-affinity FcγR genes: duplication an recombination. Science. (1990) 248:732-5. doi: 10.1126/science.2139735
4. Brooks DG, Qiu WQ, Luster AD, Ravetch JV. Structure and expression of human IgG FcRII(CD32). Functional heterogeneity is encoded by the alternatively spliced products of multiple genes. J Exp Med. (1989) 170:1369-85. doi: 10.1084/jem.170.4.1369
5. Powell MS, Barton PA, Emmanouilidis D, Wines BD, Neumann GM, Peitersz GA, et al. Biochemical analysis and crystallisation of Fc gamma RIIa, the low affinity receptor for Ig. Immunol Lett G. (1999) 68:17-23. doi: 10.1016/S0165-2478(99)00025-5
6. Bruhns P, Iannascoli B, England P, Mancardi DA, Fernandez N, Jorieux S, et al. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood. (2009) 113:3716-25. doi: 10.1182/blood-2008-09-179754
7. Lu J, Mold C, Du Clos TW, Sun PD. Pentraxins and Fc receptor-mediated immune responses. Front Immunol. (2018) 9:2607. doi: 10.3389/fimmu.2018.02607
8. Hibbs ML, Bonadonna L, Scott BM, McKenzie IF, Hogarth PM. Molecular cloning of a human immunoglobulin G Fc receptor. Proc Natl Acad Sci USA. (1988) 85:2240-4. doi: 10.1073/pnas.85.7.2240
9. Ierino FL, Hulett MD, McKenzie IF, Hogarth PM. Mapping epitopes of human Fc gamma RII (CDw32) with monoclonal antibodies and recombinant receptors. J Immunol. (1993) 150:1794-803.
10. Ierino FL, Powell MS, McKenzie IFC, Hogarth PM. Recombinant soluble human Fc gamma RII: production, characterization, and inhibition of the Arthus reaction. J Exp Med. (1993) 178:1617-28. doi: 10.1084/jem.178.5.1617
11. van der Heijden J, Geissler J, van Mirre E, van Deuren MJ, van der Meer W, Salama ATK, et al. A novel splice variant of FcgammaRIIa: a risk factor for anaphylaxis in patients with hypogammaglobulinemia. J Allergy Clin Immunol. (2013) 131:1408-16 e5. doi: 10.1016/j.jaci.2013.02.009
12. Anania JC, Trist HT, Palmer CS, Tan PS, Kouskousis BP, Chenoweth AM, et al. The rare anaphylaxis-associated FcγRIIa3 exhibits distinct characteristics from the canonical FcγRIIa1. Front Immunol. (2018) 9:1809. doi: 10.3389/fimmu.2018.01809
13. Amigorena S, Bonnerot C, Drake JR, Choquet D, Hunziker W, Guillet JG, et al. Cytoplasmic domain heterogeneity and functions of IgG Fc receptors in B lymphocytes. Science. (1992) 256:1808-12. doi: 10.1126/science.1535455
14. Astier A, de la Salle H, de la Salle C, Bieber T, Esposito-Farese ME, Freund M, et al. Human epidermal Langerhans cells secrete a soluble receptor for IgG (Fc gamma RII/CD32) that inhibits the binding of immune complexes to Fc gamma R+ cells. J Immunol. (1994) 152:201-12.
15. Trist HM, Tan PS, Wines BD, Ramsland PA, Orlowski E, Stubbs J, et al. Polymorphisms and interspecies differences of the activating and inhibitory FcgammaRII of Macaca nemestrina influence the binding of human IgG subclasses. J Immunol. (2014) 192:792-803. doi: 10.4049/jimmunol.1301554
16. Hogarth PM, Anania JC, Wines BD. The FcgammaR of humans and non-human primates and their interaction with IgG: implications for induction of inflammation, resistance to infection and the use of therapeutic monoclonal antibodies. Curr Top Microbiol Immunol. (2014) 382:321-52. doi: 10.1007/978-3-319-07911-0_15
17. Hulett MD, Hogarth PM. Molecular basis of Fc receptor function. Adv Immunol. (1994) 57:1-127. doi: 10.1016/S0065-2776(08)60671-9
18. Boruchov AM, Heller G, Veri MC, Bonvini E, Ravetch JV, Young JW. Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. J Clin Invest. (2005) 115:2914-23. doi: 10.1172/JCI24772
19. Shushakova N, Skokowa J, Schulman J, Baumann U, Zwirner J, Schmidt RE, et al. C5a anaphylatoxin is a major regulator of activating versus inhibitory FcgammaRs in immune complex-induced lung disease. J Clin Invest. (2002) 110:1823-30. doi: 10.1172/JCI16577
20. Guyre PM, Morganelli PM, Miller R. Recombinant immune interferon increases immunoglobulin G Fc receptors on cultured human mononuclear phagocytes. J Clin Invest. (1983) 72:393-7. doi: 10.1172/JCI110980
21. te Velde AA, de Waal Malefijt R, Huijbens RJ, de Vries JE, Figdor CG. IL-10 stimulates monocyte Fc gamma R surface expression and cytotoxic activity. Distinct regulation of antibody-dependent cellular cytotoxicity by IFN-gamma, IL-4, and IL-10. J Immunol. (1992) 149:4048-52.
22. Engelhardt W, Matzke J, Schmidt RE. Activation-dependent expression of low affinity IgG receptors Fc gamma RII(CD32) and Fc gamma RIII(CD16) in subpopulations of human T lymphocytes. Immunobiology. (1995) 192:297-320. doi: 10.1016/S0171-2985(11)80172-5
23. Holgado MP, Sananez I, Raiden S, Geffner JR, Arruvito L. CD32 ligation promotes the activation of CD4(+) T cells. Front Immunol. (2018) 9:2814. doi: 10.3389/fimmu.2018.02814
24. Metzger H. Transmembrane signaling: the joy of aggregation. J Immunol. (1992) 149:1477-87.
25. Getahun A, Cambier JC. Of ITIMs, ITAMs, and ITAMis: revisiting immunoglobulin Fc receptor signaling. Immunol Rev. (2015) 268:66-73. doi: 10.1111/imr.12336
26. Barrow AD, Trowsdale J. You say ITAM and I say ITIM, let's call the whole thing off: the ambiguity of immunoreceptor signalling. Eur J Immunol. (2006) 36:1646-53. doi: 10.1002/eji.200636195
27. Mkaddem SB, Murua A, Flament H, Titeca-Beauport D, Bounaix C, Danelli L, et al. Lyn and Fyn function as molecular switches that control immunoreceptors to direct homeostasis or inflammation. Nat Commun. (2017) 8:246. doi: 10.1038/s41467-017-00294-0
28. Ganesan LP, Fang H, Marsh CB, Tridandapani S. The protein-tyrosine phosphatase SHP-1 associates with the phosphorylated immunoreceptor tyrosine-based activation motif of Fc gamma RIIa to modulate signaling events in myeloid cells. J Biol Chem. (2003) 278:35710-7. doi: 10.1074/jbc.M305078200
29. Ben Mkaddem S, Hayem G, Jonsson F, Rossato E, Boedec E, Boussetta T, et al. Shifting FcgammaRIIA-ITAM from activation to inhibitory configuration ameliorates arthritis. J Clin Invest. (2014) 124:3945-59. doi: 10.1172/JCI74572
30. Campbell KS. Suppressing the killer instinct. Sci Signal. (2016) 9:fs8. doi: 10.1126/scisignal.aaf6348
31. Kanamaru Y, Pfirsch S, Aloulou M, Vrtovsnik F, Essig M, Loirat C, et al. Inhibitory ITAM signaling by Fc alpha RI-FcR gamma chain controls multiple activating responses and prevents renal inflammation. J Immunol. (2008) 180:2669-78. doi: 10.4049/jimmunol.180.4.2669
32. Rossato E, Ben Mkaddem S, Kanamaru Y, Hurtado-Nedelec M, Hayem G, Descatoire V, et al. Reversal of Arthritis by Human Monomeric IgA Through the Receptor-Mediated SH2 Domain-Containing Phosphatase 1 Inhibitory Pathway. Arthritis Rheumatol. (2015) 67:1766-77. doi: 10.1002/art.39142
33. Aloulou M, Ben Mkaddem S, Biarnes-Pelicot M, Boussetta T, Souchet H, Rossato E, et al. IgG1 and IVIg induce inhibitory ITAM signaling through FcgammaRIII controlling inflammatory responses. Blood. (2012) 119:3084-96. doi: 10.1182/blood-2011-08-376046
34. Bournazos S, Wang TT, Ravetch JV. The role and function of Fcgamma receptors on myeloid cells. Microbiol Spectr. (2016) 4:6. doi: 10.1128/microbiolspec.MCHD-0045-2016
35. Vogelpoel LT, Baeten DL, de Jong EC, den Dunnen J. Control of cytokine production by human fc gamma receptors: implications for pathogen defense and autoimmunity. Front Immunol. (2015) 6:79. doi: 10.3389/fimmu.2015.00079
36. Booth JW, Kim MK, Jankowski A, Schreiber AD, Grinstein S. Contrasting requirements for ubiquitylation during Fc receptor-mediated endocytosis and phagocytosis. EMBO J. (2002) 21:251-8. doi: 10.1093/emboj/21.3.251
37. Zhang CY, Booth JW. Differences in endocytosis mediated by FcgammaRIIA and FcgammaRIIB2. Mol Immunol. (2011) 49:329-37. doi: 10.1016/j.molimm.2011.09.003
38. Indik Z, Kelly C, Chien P, Levinson AI, Schreiber AD. Human Fc gamma RII, in the absence of other Fc gamma receptors, mediates a phagocytic signal. J Clin Invest. (1991) 88:1766-71. doi: 10.1172/JCI115496
39. Dai X, Jayapal M, Tay HK, Reghunathan R, Lin G, Too CT, et al. Differential signal transduction, membrane trafficking, and immune effector functions mediated by FcgammaRI versus FcgammaRIIa. Blood. (2009) 114:318-27. doi: 10.1182/blood-2008-10-184457
40. Huang ZY, Chien P, Indik ZK, Schreiber AD. Human platelet FcgammaRIIA and phagocytes in immune-complex clearance. Mol Immunol. (2011) 48:691-6. doi: 10.1016/j.molimm.2010.11.017
41. Chen K, Nishi H, Travers R, Tsuboi N, Martinod K, Wagner DD, et al. Endocytosis of soluble immune complexes leads to their clearance by FcgammaRIIIB but induces neutrophil extracellular traps via FcgammaRIIA in vivo. Blood. (2012) 120:4421-31. doi: 10.1182/blood-2011-12-401133
42. Worth RG, Chien CD, Chien P, Reilly MP, McKenzie SE, Schreiber AD. Platelet FcgammaRIIA binds and internalizes IgG-containing complexes. Exp Hematol. (2006) 34:1490-5. doi: 10.1016/j.exphem.2006.06.015
43. Richards JO, Karki S, Lazar GA, Chen H, Dang W, Desjarlais JR. Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells. Mol Cancer Ther. (2008) 7:2517-27. doi: 10.1158/1535-7163.MCT-08-0201
44. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med. (1994) 179:1109-18. doi: 10.1084/jem.179.4.1109
45. Wallace PK, Tsang KY, Goldstein J, Correale P, Jarry TM, Schlom J, et al. Exogenous antigen targeted to FcgammaRI on myeloid cells is presented in association with MHC class I. J Immunol Methods. (2001) 248:183-94. doi: 10.1016/S0022-1759(00)00351-3
46. Platzer B, Stout M, Fiebiger E. Antigen cross-presentation of immune complexes. Front Immunol. (2014) 5:140. doi: 10.3389/fimmu.2014.00140
47. Amigorena S. Fc gamma receptors and cross-presentation in dendritic cells. J Exp Med. (2002) 195:F1-3. doi: 10.1084/jem.20011925
48. DiLillo DJ, Ravetch JV. Differential Fc-receptor engagement drives an anti-tumor vaccinal effect. Cell. (2015) 161:1035-45. doi: 10.1016/j.cell.2015.04.016
49. Graziano RF, Fanger MW. Fc gamma RI and Fc gamma RII on monocytes and granulocytes are cytotoxic trigger molecules for tumor cells. J Immunol. (1987) 139:3536-41.
50. Krutmann J, Kirnbauer R, Kock A, Schwarz T, Schopf E, May LT, et al. Cross-linking Fc receptors on monocytes triggers IL-6 production. Role in anti-CD3-induced T cell activation. J Immunol. (1990) 145:1337-42.
51. Simms HH, Gaither TA, Fries LF, Frank MM. Monokines released during short-term Fc gamma receptor phagocytosis up-regulate polymorphonuclear leukocytes and monocyte-phagocytic function. J Immunol. (1991) 147:265-72.
52. Osuna CE, Lim SY, Kublin JL, Apps R, Chen E, Mota TM, et al. Evidence that CD32a does not mark the HIV-1 latent reservoir. Nature. (2018) 561:E20-8. doi: 10.1038/s41586-018-0495-2
53. Chauhan AK. Human CD4(+) T-cells: a role for low-affinity Fc receptors. Front Immunol. (2016) 7:215. doi: 10.3389/fimmu.2016.00215
54. Canobbio I, Stefanini L, Guidetti GF, Balduini C, Torti M. A new role for FcgammaRIIA in the potentiation of human platelet activation induced by weak stimulation. Cell Signal. (2006) 18:861-70. doi: 10.1016/j.cellsig.2005.07.014
55. Gardiner EE, Karunakaran D, Arthur JF, Mu FT, Powell MS, Baker RI, et al. Dual ITAM-mediated proteolytic pathways for irreversible inactivation of platelet receptors: de-ITAM-izing FcgammaRIIa. Blood. (2008) 111:165-74. doi: 10.1182/blood-2007-04-086983
56. Hibbs ML, Walker ID, Kirszbaum L, Pietersz GA, Deacon NJ, Chambers GW, et al. The murine Fc receptor for immunoglobulin: purification, partial amino acid sequence, and isolation of cDNA clones. Proc Natl Acad Sci USA. (1986) 83:6980-4. doi: 10.1073/pnas.83.18.6980
57. Lewis VA, Koch T, Plutner H, Mellman I. A complementary DNA clone for a macrophage-lymphocyte Fc receptor. Nature. (1986) 324:372-5. doi: 10.1038/324372a0
58. Latour S, Fridman WH, Daeron M. Identification, molecular cloning, biologic properties, and tissue distribution of a novel isoform of murine low-affinity IgG receptor homologous to human Fc gamma RIIB1. J Immunol. (1996) 157:189-97.
59. Su K, Yang H, Li X, Li X, Gibson AW, Cafardi JM, et al. Expression profile of FcgammaRIIb on leukocytes and its dysregulation in systemic lupus erythematosus. J Immunol. (2007) 178:3272-80. doi: 10.4049/jimmunol.178.5.3272
60. Veri MC, Gorlatov S, Li H, Burke S, Johnson S, Stavenhagen J, et al. Monoclonal antibodies capable of discriminating the human inhibitory Fcgamma-receptor IIB (CD32B) from the activating Fcgamma-receptor IIA (CD32A): biochemical, biological and functional characterization. Immunology. (2007) 121:392-404. doi: 10.1111/j.1365-2567.2007.02588.x
61. Ramsland PA, Farrugia W, Bradford TM, Sardjono CT, Esparon S, Trist HM, et al. Structural basis for Fc gammaRIIa recognition of human IgG and formation of inflammatory signaling complexes. J Immunol. (2011) 187:3208-17. doi: 10.4049/jimmunol.1101467
62. Joshi T, Ganesan LP, Cao X, Tridandapani S. Molecular analysis of expression and function of hFcgammaRIIbl and b2 isoforms in myeloid cells. Mol Immunol. (2006) 43:839-50. doi: 10.1016/j.molimm.2005.06.037
63. Tsang MW, Nagelkerke SQ, Bultink IE, Geissler J, Tanck MW, Tacke CE, et al. Fc-gamma receptor polymorphisms differentially influence susceptibility to systemic lupus erythematosus and lupus nephritis. Rheumatology. (2016) 55:939-48. doi: 10.1093/rheumatology/kev433
64. Sellge G, Barkowsky M, Kramer S, Gebhardt T, Sander LE, Lorentz A, et al. Interferon-gamma regulates growth and controls Fcgamma receptor expression and activation in human intestinal mast cells. BMC Immunol. (2014) 15:27. doi: 10.1186/1471-2172-15-27
65. Burton OT, Epp A, Fanny ME, Miller SJ, Stranks AJ, Teague JE, et al. Tissue-specific expression of the low-affinity IgG receptor, FcgammaRIIb, on human mast cells. Front Immunol. (2018) 9:1244. doi: 10.3389/fimmu.2018.01244
66. Zhao W, Kepley CL, Morel PA, Okumoto LM, Fukuoka Y, Schwartz LB. Fc gamma RIIa, not Fc gamma RIIb, is constitutively and functionally expressed on skin-derived human mast cells. J Immunol. (2006) 177:694-701. doi: 10.4049/jimmunol.177.1.694
67. van der Heijden J, Breunis WB, Geissler J, de Boer M, van den Berg TK, Kuijpers TW. Phenotypic variation in IgG receptors by nonclassical FCGR2C alleles. J Immunol. (2012) 188:1318-24. doi: 10.4049/jimmunol.1003945
68. Xia YC, Schuliga M, Shepherd M, Powell M, Harris T, Langenbach SY, Tan PS, et al. Functional expression of IgG-Fc receptors in human airway smooth muscle cells. Am J Respir Cell Mol Biol. (2011) 44:665-72. doi: 10.1165/rcmb.2009-0371OC
69. Ganesan LP, Kim J, Wu Y, Mohanty S, Phillips GS, Birmingham DJ, et al. FcgammaRIIb on liver sinusoidal endothelium clears small immune complexes. J Immunol. (2012) 189:4981-8. doi: 10.4049/jimmunol.1202017
70. Iwayanagi Y, Igawa T, Maeda A, Haraya K, Wada NA, Shibahara N, et al. Inhibitory FcgammaRIIb-mediated soluble antigen clearance from plasma by a pH-dependent antigen-binding antibody and its enhancement by Fc engineering. J Immunol. (2015) 195:3198-205. doi: 10.4049/jimmunol.1401470
71. Chu SY, Horton HM, Pong E, Leung IW, Chen H, Nguyen DH, et al. Reduction of total IgE by targeted coengagement of IgE B-cell receptor and FcgammaRIIb with Fc-engineered antibody. J Allergy Clin Immunol. (2012) 129:1102-15. doi: 10.1016/j.jaci.2011.11.029
72. Phillips NE, Parker DC. Fc-dependent inhibition of mouse B cell activation by whole anti-mu antibodies. J Immunol. (1983) 130:602-6.
73. Tiller T, Kofer J, Kreschel C, Busse CE, Riebel S, Wickert S, et al. Development of self-reactive germinal center B cells and plasma cells in autoimmune Fc gammaRIIB-deficient mice. J Exp Med. (2010) 207:2767-78. doi: 10.1084/jem.20100171
74. Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol. (2008) 8:34-47. doi: 10.1038/nri2206
75. Baerenwaldt A, Lux A, Danzer H, Spriewald BM, Ullrich E, Heidkamp G, et al. Fcgamma receptor IIB (FcgammaRIIB) maintains humoral tolerance in the human immune system in vivo. Proc Natl Acad Sci USA. (2011) 108:18772-7. doi: 10.1073/pnas.1111810108
76. Daeron M, Lesourne R. Negative signaling in Fc receptor complexes. Adv Immunol. (2006) 89:39-86. doi: 10.1016/S0065-2776(05)89002-9
77. Liu Y, Masuda E, Blank MC, Kirou KA, Gao X, Park MS, et al. Cytokine-mediated regulation of activating and inhibitory Fc gamma receptors in human monocytes. J Leukoc Biol. (2005) 77:767-76. doi: 10.1189/jlb.0904532
78. Espeli M, Smith KG, Clatworthy MR. FcgammaRIIB and autoimmunity. Immunol Rev. (2016) 269:194-211. doi: 10.1111/imr.12368
79. Hunter S, Indik ZK, Kim MK, Cauley MD, Park JG, Schreiber AD. Inhibition of Fcgamma receptor-mediated phagocytosis by a nonphagocytic Fcgamma receptor. Blood. (1998) 91:1762-8.
80. Malbec O, Fong DC, Turner M, Tybulewicz VL, Cambier JC, Fridman WH, et al. Fc epsilon receptor I-associated lyn-dependent phosphorylation of Fc gamma receptor IIB during negative regulation of mast cell activation. J Immunol. (1998) 160:1647-58.
81. Bewarder N, Weinrich V, Budde P, Hartmann D, Flaswinkel H, Reth M, et al. In vivo and in vitro specificity of protein tyrosine kinases for immunoglobulin G receptor (FcgammaRII) phosphorylation. Mol Cell Biol. (1996) 16:4735-43. doi: 10.1128/MCB.16.9.4735
82. Lesourne R, Bruhns P, Fridman WH, Daeron M. Insufficient phosphorylation prevents fc gamma RIIB from recruiting the SH2 domain-containing protein-tyrosine phosphatase SHP-1. J Biol Chem. (2001) 276:6327-36. doi: 10.1074/jbc.M006537200
83. Isnardi I, Lesourne R, Bruhns P, Fridman WH, Cambier JC, Daeron M. Two distinct tyrosine-based motifs enable the inhibitory receptor FcgammaRIIB to cooperatively recruit the inositol phosphatases SHIP1/2 and the adapters Grb2/Grap. J Biol Chem. (2004) 279:51931-8. doi: 10.1074/jbc.M410261200
84. Isnardi I, Bruhns P, Bismuth G, Fridman WH, Daeron M. The SH2 domain-containing inositol 5-phosphatase SHIP1 is recruited to the intracytoplasmic domain of human FcgammaRIIB and is mandatory for negative regulation of B cell activation. Immunol Lett. (2006) 104:156-65. doi: 10.1016/j.imlet.2005.11.027
85. Aman MJ, Tosello-Trampont AC, Ravichandran K. Fc gamma RIIB1/SHIP-mediated inhibitory signaling in B cells involves lipid rafts. J Biol Chem. (2001) 276:46371-8. doi: 10.1074/jbc.M104069200
86. Fong DC, Brauweiler A, Minskoff SA, Bruhns P, Tamir I, Mellman I, et al. Mutational analysis reveals multiple distinct sites within Fc gamma receptor IIB that function in inhibitory signaling. J Immunol. (2000) 165:4453-62. doi: 10.4049/jimmunol.165.8.4453
87. Wang J, Li Z, Xu L, Yang H, Liu W. Transmembrane domain dependent inhibitory function of FcgammaRII. Protein Cell B. (2018) 9:1004-12. doi: 10.1007/s13238-018-0509-8
88. Xiang Z, Cutler AJ, Brownlie RJ, Fairfax K, Lawlor KE, Severinson E, et al. FcgammaRIIb controls bone marrow plasma cell persistence and apoptosis. Nat Immunol. (2007) 8:419-29. doi: 10.1038/ni1440
89. Gast M, Preisinger C, Nimmerjahn F, Huber M. IgG-independent Co-aggregation of FcepsilonRI and FcgammaRIIB Results in LYN- and SHIP1-dependent tyrosine phosphorylation of FcgammaRIIB in murine bone marrow-derived mast cells. Front Immunol. (2018) 9:1937. doi: 10.3389/fimmu.2018.01937
90. Lehmann B, Schwab I, Bohm S, Lux A, Biburger M, Nimmerjahn F. FcgammaRIIB: a modulator of cell activation and humoral tolerance. Expert Rev Clin Immunol. (2012) 8:243-54. doi: 10.1586/eci.12.5
91. Malbec O, Daeron M. The mast cell IgG receptors and their roles in tissue inflammation. Immunol Rev. (2007) 217:206-21. doi: 10.1111/j.1600-065X.2007.00510.x
92. Miettinen HM, Matter K, Hunziker W, Rose JK, Mellman I. Fc receptor endocytosis is controlled by a cytoplasmic domain determinant that actively prevents coated pit localization. J Cell Biol. (1992) 116:875-88. doi: 10.1083/jcb.116.4.875
93. Budde P, Bewarder N, Weinrich V, Schulzeck O, Frey J. Tyrosine-containing sequence motifs of the human immunoglobulin G receptors FcRIIb1 and FcRIIb2 essential for endocytosis and regulation of calcium flux in B cells. J Biol Chem. (1994) 269:30636-44.
94. Hunziker W, Fumey C. A di-leucine motif mediates endocytosis and basolateral sorting of macrophage IgG Fc receptors in MDCK cells. EMBO J. (1994) 13:2963-9. doi: 10.1002/j.1460-2075.1994.tb06594.x
95. Van Den Herik-Oudijk JG, Westerdaal NA, Henriquez NV, Capel PJ, Van De Winkel IE. Functional analysis of human Fc gamma RII (CD32) isoforms expressed in B lymphocytes. J Immunol. (1994) 152:574-85.
96. Warmerdam PA, van den Herik-Oudijk IE, Parren PW, Westerdaal NA, van de Winkel JG, Capel PJ. Interaction of a human Fc gamma RIIb1 (CD32) isoform with murine and human IgG subclasses. Int Immunol. (1993) 5:239-47. doi: 10.1093/intimm/5.3.239
97. Pearse RN, Kawabe T, Bolland S, Guinamard R, Kurosaki T, Ravetch JV. SHIP recruitment attenuates Fc gamma RIIB-induced B cell apoptosis. Immunity. (1999) 10:753-60. doi: 10.1016/S1074-7613(00)80074-6
98. Fakher M, Wu J, Qin D, Szakal A, Tew J. Follicular dendritic cell accessory activity crosses MHC and species barriers. Eur J Immunol. (2001) 31:176-85. doi: 10.1002/1521-4141(200101)31:1<176::AID-IMMU176>3.0.CO;2-H
99. Sukumar S, El Shikh ME, Tew JG, Szakal AK. Ultrastructural study of highly enriched follicular dendritic cells reveals their morphology and the periodicity of immune complex binding. Cell Tissue Res. (2008) 332:89-99. doi: 10.1007/s00441-007-0566-4
100. El Shikh ME, El Sayed RM, Sukumar S, Szakal AK, Tew JG. Activation of B cells by antigens on follicular dendritic cells. Trends Immunol. (2010) 31:205-11. doi: 10.1016/j.it.2010.03.002
101. Cassard L, Jonsson F, Arnaud S, Daeron M. Fcgamma receptors inhibit mouse and human basophil activation. J Immunol. (2012) 189:2995-3006. doi: 10.4049/jimmunol.1200968
102. Cady CT, Powell MS, Harbeck RJ, Giclas PC, Murphy JR, Katial RK, et al. IgG antibodies produced during subcutaneous allergen immunotherapy mediate inhibition of basophil activation via a mechanism involving both FcgammaRIIA and FcgammaRII. Immunol Lett B. (2010) 130:57-65. doi: 10.1016/j.imlet.2009.12.001
103. Wijngaarden S, van de Winkel JG, Jacobs KM, Bijlsma JW, Lafeber FP, van Roon JA. A shift in the balance of inhibitory and activating Fcgamma receptors on monocytes toward the inhibitory Fcgamma receptor IIb is associated with prevention of monocyte activation in rheumatoid arthritis. Arthritis Rheum. (2004) 50:3878-87. doi: 10.1002/art.20672
104. Clynes R, Maizes JS, Guinamard R, Ono M, Takai T, Ravetch JV. Modulation of immune complex-induced inflammation in vivo by the coordinate expression of activation and inhibitory Fc receptors. J Exp Med. (1999) 189:179-85. doi: 10.1084/jem.189.1.179
105. Metes D, Ernst LK, Chambers WH, Sulica A, Herberman RB, Morel PA. Expression of functional CD32 molecules on human NK cells is determined by an allelic polymorphism of the FcgammaRIIC gene. Blood. (1998) 91:2369-80.
106. Breunis WB, van Mirre E, Bruin M, Geissler J, de Boer M, Peters M, et al. Copy number variation of the activating FCGR2C gene predisposes to idiopathic thrombocytopenic purpura. Blood. (2008) 111:1029-38. doi: 10.1182/blood-2007-03-079913
107. Ernst LK, Metes D, Herberman RB, Morel PA. Allelic polymorphisms in the FcgammaRIIC gene can influence its function on normal human natural killer cells. J Mol Med. (2002) 80:248-57. doi: 10.1007/s00109-001-0294-2
108. Li X, Wu J, Ptacek T, Redden DT, Brown EE, Alarcon GS, et al. Allelic-dependent expression of an activating Fc receptor on B cells enhances humoral immune responses. Sci Transl Med. (2013) 5:216ra175. doi: 10.1126/scitranslmed.3007097
109. Peng X, Li SS, Gilbert PB, Geraghty DE, Katze MG. FCGR2C Polymorphisms associated with HIV-1 vaccine protection are linked to altered gene expression of Fc-gamma receptors in human B cells. PLoS ONE. (2016) 11:e0152425. doi: 10.1371/journal.pone.0152425
110. Warncke M, Calzascia T, Coulot M, Balke N, Touil R, Kolbinger F, et al. Different adaptations of IgG effector function in human and nonhuman primates and implications for therapeutic antibody treatment. J Immunol. (2012) 188:4405-11. doi: 10.4049/jimmunol.1200090
111. Wines BD, Vanderven HA, Esparon SE, Kristensen AB, Kent SJ, Hogarth PM. Dimeric FcgammaR ectodomains as probes of the Fc receptor function of anti-influenza virus Ig. J Immunol G. (2016) 197:1507-16. doi: 10.4049/jimmunol.1502551
112. Lux A, Yu X, Scanlan CN, Nimmerjahn F. Impact of immune complex size and glycosylation on IgG binding to human FcgammaRs. J Immunol. (2013) 190:4315-23. doi: 10.4049/jimmunol.1200501
113. Wines BD, Tan CW, Duncan E, McRae S, Baker RI, Andrews RK, et al. Dimeric FcgammaR ectodomains detect pathogenic anti-platelet factor 4-heparin antibodies in heparin-induced thromobocytopenia. J Thromb Haemost. (2018) 16:2520-25. doi: 10.1111/jth.14306
114. Bournazos S, Hart SP, Chamberlain LH, Glennie MJ, Dransfield I. Association of FcgammaRIIa (CD32a) with lipid rafts regulates ligand binding activity. J Immunol. (2009) 182:8026-36. doi: 10.4049/jimmunol.0900107
115. Kanters D, ten Hove W, Luijk B, van Aalst C, Schweizer RC, Lammers JW, et al. Expression of activated Fc gamma RII discriminates between multiple granulocyte-priming phenotypes in peripheral blood of allergic asthmatic subjects. J Allergy Clin Immunol. (2007) 120:1073-81. doi: 10.1016/j.jaci.2007.06.021
116. Graziano RF, Looney RJ, Shen L, Fanger MW. Fc gamma R-mediated killing by eosinophils. J Immunol. (1989) 142:230-5.
117. Nagarajan S, Venkiteswaran K, Anderson M, Sayed U, Zhu C, Selvaraj P. Cell-specific, activation-dependent regulation of neutrophil CD32A ligand-binding function. Blood. (2000) 95:1069-77.
118. Maxwell KF, Powell MS, Hulett MD, Barton PA, McKenzie IF, Garrett TP, et al. Crystal structure of the human leukocyte Fc receptor, Fc gammaRIIa. Nat Struct Biol. (1999) 6:437-42. doi: 10.1038/8241
119. Brandsma AM, Schwartz SL, Wester MJ, Valley CC, Blezer GL A, Vidarsson G, et al. Mechanisms of inside-out signaling of the high-affinity IgG receptor FcgammaR. Sci Signal I. (2018) 11:540. doi: 10.1126/scisignal.aaq0891
120. Lu J, Sun PD. Structural mechanism of high affinity FcgammaRI recognition of immunoglobulin. Immunol Rev G. (2015) 268:192-200. doi: 10.1111/imr.12346
121. Radaev S, Sun P. Recognition of immunoglobulins by Fcgamma receptors. Mol Immunol. (2002) 38:1073-83. doi: 10.1016/S0161-5890(02)00036-6
122. Sondermann P, Oosthuizen V. X-ray crystallographic studies of IgG-Fc gamma receptor interactions. Biochem Soc Trans. (2002) 30:481-6. doi: 10.1042/bst0300481
123. Mimoto F, Igawa T, Kuramochi T, Katada H, Kadono S, Kamikawa T, et al. Novel asymmetrically engineered antibody Fc variant with superior FcgammaR binding affinity and specificity compared with afucosylated Fc variant. MAbs. (2013) 5:229-36. doi: 10.4161/mabs.23452
124. Caaveiro JM, Kiyoshi M, Tsumoto K. Structural analysis of Fc/FcgammaR complexes: a blueprint for antibody design. Immunol Rev. (2015) 268:201-21. doi: 10.1111/imr.12365
125. Warnerdanm OAM, van de Winkel J, Gosselin EJ, Capel JG. Molecular basis for a polymorphism of human Fc gamma receptor II (CD32). J Exp Med. (1990) 172:19-25. doi: 10.1084/jem.172.1.19
126. Norris CF, Pricop L, Millard SS, Taylor SM, Surrey S, Schwartz E, et al. A naturally occurring mutation in Fc gamma RIIA: a Q to K127 change confers unique IgG binding properties to the R131 allelic form of the receptor. Blood. (1998) 91:656-62.
127. Flinsenberg TW, Janssen WJ, Herczenik E, Boross P, Nederend M, Jongeneel LH, et al. A novel FcgammaRIIa Q27W gene variant is associated with common variable immune deficiency through defective FcgammaRIIa downstream signaling. Clin Immunol. (2014) 155:108-17. doi: 10.1016/j.clim.2014.09.006
128. Warmerdam PA, van de Winkel JG, Vlug A, Westerdaal NA, Capel PJ. A single amino acid in the second Ig-like domain of the human Fc gamma receptor II is critical for human IgG2 binding. J Immunol. (1991) 147:1338-43.
129. Parren PW, Warmerdam PA, Boeije LC, Arts J, Westerdaal NA, Vlug A, et al. On the interaction of IgG subclasses with the low affinity Fc gamma RIIa (CD32) on human monocytes, neutrophils, and platelets. Analysis of a functional polymorphism to human IgG2. J Clin Invest. (1992) 90:1537-46. doi: 10.1172/JCI116022
130. Kuo HC, Hsu YW, Wu MS, Woon PY, Wong HS, Tsai LJ, et al. FCGR2A promoter methylation and risks for intravenous immunoglobulin treatment responses in kawasaki disease. Mediators Inflamm. (2015) 2015:564625. doi: 10.1155/2015/564625
131. Su K, Wu J, Edberg JC, Li X, Ferguson P, Cooper GS, et al. A promoter haplotype of the immunoreceptor tyrosine-based inhibitory motif-bearing FcgammaRIIb alters receptor expression and associates with autoimmunity. I. Regulatory FCGR2B polymorphisms and their association with systemic lupus erythematosus. J Immunol. (2004) 172:7186-91. doi: 10.4049/jimmunol.172.11.7186
132. Willcocks LC, Carr EJ, Niederer HA, Rayner TF, Williams TN, Yang W, et al. A defunctioning polymorphism in FCGR2B is associated with protection against malaria but susceptibility to systemic lupus erythematosus. Proc Natl Acad Sci USA. (2010) 107:7881-5. doi: 10.1073/pnas.0915133107
133. Floto RA, Clatworthy MR, Heilbronn KR, Rosner DR, MacAry PA, Rankin A, et al. Loss of function of a lupus-associated FcgammaRIIb polymorphism through exclusion from lipid rafts. Nat Med. (2005) 11:1056-8. doi: 10.1038/nm1288
134. Kyogoku C, Dijstelbloem HM, Tsuchiya N, Hatta Y, Kato H, Yamaguchi A, et al. Fcgamma receptor gene polymorphisms in Japanese patients with systemic lupus erythematosus: contribution of FCGR2B to genetic susceptibility. Arthritis Rheum. (2002) 46:1242-54. doi: 10.1002/art.10257
135. Li X, Wu J, Carter RH, Edberg JC, Su K, Cooper GS, et al. A novel polymorphism in the Fcgamma receptor IIB (CD32B) transmembrane region alters receptor signaling. Arthritis Rheum. (2003) 48:3242-52. doi: 10.1002/art.11313
136. Kono H, Kyogoku C, Suzuki T, Tsuchiya N, Honda H, Yamamoto K, et al. FcgammaRIIB Ile232Thr transmembrane polymorphism associated with human systemic lupus erythematosus decreases affinity to lipid rafts and attenuates inhibitory effects on B cell receptor signaling. Hum Mol Genet. (2005) 14:2881-92. doi: 10.1093/hmg/ddi320
137. Xu L, Xia M, Guo J, Sun X, Li H, Xu C, et al. Impairment on the lateral mobility induced by structural changes underlies the functional deficiency of the lupus-associated polymorphism FcgammaRIIB-T232. J Exp Med. (2016) 213:2707-27. doi: 10.1084/jem.20160528
138. Li SS, Gilbert PB, Tomaras GD, Kijak G, Ferrari G, Thomas R, et al. FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial. J Clin Invest. (2014) 124:3879-90. doi: 10.1172/JCI75539
139. Kaifu T, Nakamura A. Polymorphisms of immunoglobulin receptors and the effects on clinical outcome in cancer immunotherapy and other immune diseases: a general review. Int Immunol. (2017) 29:319-325. doi: 10.1093/intimm/dxx041
140. Li X, Gibson AW, Kimberly RP. Human FcR polymorphism and disease. Curr Top Microbiol Immunol. (2014) 382:275-302. doi: 10.1007/978-3-319-07911-0_13
141. Li X, Kimberly RP. Targeting the Fc receptor in autoimmune disease. Expert Opin Ther Targets. (2014) 18:335-50. doi: 10.1517/14728222.2014.877891
142. Nakamura A, Kubo T, Takai T. Fc receptor targeting in the treatment of allergy, autoimmune diseases and cancer. Adv Exp Med Biol. (2008) 640:220-33. doi: 10.1007/978-0-387-09789-3_17
143. Willcocks LC, Smith KG, Clatworthy MR. Low-affinity Fcgamma receptors, autoimmunity and infection. Expert Rev Mol Med. (2009) 11:e24. doi: 10.1017/s1462399409001161
144. Rodriguez ME, van der Pol WL, Sanders LA, van de Winkel JG. Crucial role of FcgammaRIIa (CD32) in assessment of functional anti-Streptococcus pneumoniae antibody activity in human sera. J Infect Dis. (1999) 179:423-33. doi: 10.1086/314603
145. Yuan FF, Wong M, Pererva N, Keating J, Davis AR, Bryant JA, et al. FcgammaRIIA polymorphisms in Streptococcus pneumoniae infection. Immunol Cell Biol. (2003) 81:192-5. doi: 10.1046/j.1440-1711.2003.01158.x
146. Pathan N, Faust SN, Levin M. Pathophysiology of meningococcal meningitis and septicaemia. Arch Dis Child. (2003) 88:601-7. doi: 10.1136/adc.88.7.601
147. Nicu EA, Van der Velden U, Everts V, Van Winkelhoff AJ, Roos D, Loos BG. Hyper-reactive PMNs in FcgammaRIIa 131 H/H genotype periodontitis patients. J Clin Periodontol. (2007) 34:938-45. doi: 10.1111/j.1600-051X.2007.01136.x
148. van Egmond M, Vidarsson G, Bakema JE. Cross-talk between pathogen recognizing Toll-like receptors and immunoglobulin Fc receptors in immunity. Immunol Rev. (2015) 268:311-27. doi: 10.1111/imr.12333
149. Wenink MH, Santegoets KC, Roelofs MF, Huijbens R, Koenen HJ, van Beek R, et al. The inhibitory Fc gamma IIb receptor dampens TLR4-mediated immune responses and is selectively up-regulated on dendritic cells from rheumatoid arthritis patients with quiescent disease. J Immunol. (2009) 183:4509-20. doi: 10.4049/jimmunol.0900153
150. Bakema JE, Tuk CW, van Vliet SJ, Bruijns SC, Vos JB, Letsiou S, et al. Antibody-opsonized bacteria evoke an inflammatory dendritic cell phenotype and polyfunctional Th cells by crosstalk between TLRs and FcRs. J Immunol. (2015) 194:1856-66. doi: 10.4049/jimmunol.1303126
151. French MA, Tanaskovic S, Law MG, Lim A, Fernandez S, Ward LD, et al. Vaccine-induced IgG2 anti-HIV p24 is associated with control of HIV in patients with a 'high-affinity' FcgammaRIIa genotype. AIDS. (2010) 24:1983-90. doi: 10.1097/QAD.0b013e32833c1ce0
152. Forthal DN, Gabriel EE, Wang A, Landucci G, Phan TB. Association of Fcgamma receptor IIIa genotype with the rate of HIV infection after gp120 vaccination. Blood. (2012) 120:2836-42. doi: 10.1182/blood-2012-05-431361
153. Sips M, Krykbaeva M, Diefenbach TJ, Ghebremichael M, Bowman BA, Dugast AS, et al. Fc receptor-mediated phagocytosis in tissues as a potent mechanism for preventive and therapeutic HIV vaccine strategies. Mucosal Immunol. (2016) 9:1584-95. doi: 10.1038/mi.2016.12
154. Brouwer KC, Lal AA, Mirel LB, Otieno J, Ayisi J, Van Eijk AM, et al. Polymorphism of Fc receptor IIa for immunoglobulin G is associated with placental malaria in HIV-1-positive women in western Kenya. J Infect Dis. (2004) 190:1192-8. doi: 10.1086/422850
155. Groux H, Gysin J. Opsonization as an effector mechanism in human protection against asexual blood stages of Plasmodium falciparum: functional role of IgG subclasses. Res Immunol. (1990) 141:529-42. doi: 10.1016/0923-2494(90)90021-P
156. Brouwer KC, Lal RB, Mirel LB, Yang C, van Eijk AM, Ayisi J, et al. Polymorphism of Fc receptor IIa for IgG in infants is associated with susceptibility to perinatal HIV-1 infection. AIDS. (2004) 18:1187-94. doi: 10.1097/00002030-200405210-00012
157. Descours B, Petitjean G, Lopez-Zaragoza JL, Bruel T, Raffel R, Psomas C, et al. CD32a is a marker of a CD4 T-cell HIV reservoir harbouring replication-competent proviruses. Nature. (2017) 543:564-7. doi: 10.1038/nature21710
158. Perez L, Anderson J, Chipman J, Thorkelson A, Chun TW, Moir S, et al. Conflicting evidence for HIV enrichment in CD32(+) CD4 T cells. Nature. (2018) 561:E9-16. doi: 10.1038/s41586-018-0493-4
159. Abdel-Mohsen M, Kuri-Cervantes L, Grau-Exposito J, Spivak AM, Nell RA, Tomescu C, et al. CD32 is expressed on cells with transcriptionally active HIV but does not enrich for HIV DNA in resting T cells. Sci Transl Med. (2018) 10:437. doi: 10.1126/scitranslmed.aar6759
160. Gan ES, Ting DH, Chan KR. The mechanistic role of antibodies to dengue virus in protection and disease pathogenesis. Expert Rev Anti Infect Ther. (2017) 15:111-9. doi: 10.1080/14787210.2017.1254550
161. Chan KR, Zhang SL, Tan HC, Chan YK, Chow A, Lim AP, et al. Ligation of Fc gamma receptor IIB inhibits antibody-dependent enhancement of dengue virus infection. Proc Natl Acad Sci USA. (2011) 108:12479-84. doi: 10.1073/pnas.1106568108
162. Boonnak K, Slike BM, Donofrio GC, Marovich MA. Human FcgammaRII cytoplasmic domains differentially influence antibody-mediated dengue virus infection. J Immunol. (2013) 190:5659-65. doi: 10.4049/jimmunol.1203052
163. Clatworthy MR, Smith KG. FcgammaRIIb balances efficient pathogen clearance and the cytokine-mediated consequences of sepsis. J Exp Med. (2004) 199:717-23. doi: 10.1084/jem.20032197
164. Brownlie RJ, Lawlor KE, Niederer HA, Cutler AJ, Xiang Z, Clatworthy MR, et al. Distinct cell-specific control of autoimmunity and infection by FcgammaRIIb. J Exp Med. (2008) 205:883-95. doi: 10.1084/jem.20072565
165. Bave U, Magnusson M, Eloranta ML, Perers A, Alm GV, Ronnblom L. Fc gamma RIIa is expressed on natural IFN-alpha-producing cells (plasmacytoid dendritic cells) and is required for the IFN-alpha production induced by apoptotic cells combined with lupus Ig. J Immunol G. (2003) 171:3296-302. doi: 10.4049/jimmunol.171.6.3296
166. Yu X, Lazarus AH. Targeting FcgammaRs to treat antibody-dependent autoimmunity. Autoimmun Rev. (2016) 15:510-2. doi: 10.1016/j.autrev.2016.02.006
167. Smith KG, Clatworthy MR. FcgammaRIIB in autoimmunity and infection: evolutionary and therapeutic implications. Nat Rev Immunol. (2010) 10:328-43. doi: 10.1038/nri2762
168. van der Pol WL, van den Berg LH, Scheepers RH, van der Bom JG, van Doorn PA, van Koningsveld R, et al. IgG receptor IIa alleles determine susceptibility and severity of Guillain-Barre syndrome. Neurology. (2000) 54:1661-5. doi: 10.1212/WNL.54.8.1661
169. Khor CC, Davila S, Breunis WB, Lee YC, Shimizu C, Wright VJ, et al. Genome-wide association study identifies FCGR2A as a susceptibility locus for Kawasaki disease. Nat Genet. (2011) 43:1241-6. doi: 10.1038/ng.981
170. Asano K, Matsushita T, Umeno J, Hosono N, Takahashi A, Kawaguchi T, et al. A genome-wide association study identifies three new susceptibility loci for ulcerative colitis in the Japanese population. Nat Genet. (2009) 41:1325-9. doi: 10.1038/ng.482
171. Raaz D, Herrmann M, Ekici AB, Klinghammer L, Lausen B, Voll RE, et al. FcgammaRIIa genotype is associated with acute coronary syndromes as first manifestation of coronary artery disease. Atherosclerosis. (2009) 205:512-6. doi: 10.1016/j.atherosclerosis.2009.01.013
172. Karassa FB, Bijl M, Davies KA, Kallenberg CG, Khamashta MA, Manger K, et al. Role of the Fcgamma receptor IIA polymorphism in the antiphospholipid syndrome: an international meta-analysis. Arthritis Rheum. (2003) 48:1930-8. doi: 10.1002/art.11059
173. Raaz-Schrauder D, Ekici AB, Munoz LE, Klinghammer L, Voll RE, Leusen JH, et al. Patients with unstable angina pectoris show an increased frequency of the Fc gamma RIIa R131 allele. Autoimmunity. (2012) 45:556-64. doi: 10.3109/08916934.2012.682665
174. van der Pol WL, Jansen MD, Kuks JB, de Baets M, Leppers-van de Straat, Wokke JH, et al. Association of the Fc gamma receptor IIA-R/R131 genotype with myasthenia gravis in Dutch patients. J Neuroimmunol. (2003) 144:143-7. doi: 10.1016/j.jneuroim.2003.08.043
175. Mathsson L, Lampa J, Mullazehi M, Ronnelid J. Immune complexes from rheumatoid arthritis synovial fluid induce FcgammaRIIa dependent and rheumatoid factor correlated production of tumour necrosis factor-alpha by peripheral blood mononuclear cells. Arthritis Res Ther. (2006) 8:R64. doi: 10.1186/ar1926
176. Ronnelid J, Tejde A, Mathsson L, Nilsson-Ekdahl K, Nilsson B. Immune complexes from SLE sera induce IL10 production from normal peripheral blood mononuclear cells by an FcgammaRII dependent mechanism: implications for a possible vicious cycle maintaining B cell hyperactivity in SLE. Ann Rheum Dis. (2003) 62:37-42. doi: 10.1136/ard.62.1.37
177. Chang LS, Lo MH, Li SC, Yang MY, Hsieh KS, Kuo HC. The effect of FcgammaRIIA and FcgammaRIIB on coronary artery lesion formation and intravenous immunoglobulin treatment responses in children with Kawasaki disease. Oncotarget. (2017) 8:2044-52. doi: 10.18632/oncotarget.13489
178. Stewart-Akers AM, Cunningham A, Wasko MC, Morel PA. Fc gamma R expression on NK cells influences disease severity in rheumatoid arthritis. Genes Immun. (2004) 5:521-9. doi: 10.1038/sj.gene.6364121
179. Blank MC, Stefanescu RN, Masuda E, Marti F, King PD, Redecha PB, et al. Decreased transcription of the human FCGR2B gene mediated by the−343 G/C promoter polymorphism and association with systemic lupus erythematosus. Hum Genet. (2005) 117:220-7. doi: 10.1007/s00439-005-1302-3
180. Radstake TR, Franke B, Wenink MH, Nabbe KC, Coenen MJ, Welsing P, et al. The functional variant of the inhibitory Fcgamma receptor IIb (CD32B) is associated with the rate of radiologic joint damage and dendritic cell function in rheumatoid arthritis. Arthritis Rheum. (2006) 54:3828-37. doi: 10.1002/art.22275
181. Xu L, Li G, Wang J, Fan Y, Wan Z, Zhang S, et al. Through an ITIM-independent mechanism the FcgammaRIIB blocks B cell activation by disrupting the colocalized microclustering of the B cell receptor and CD19. J Immunol. (2014) 192:5179-91. doi: 10.4049/jimmunol.1400101
182. Cassard L, Cohen-Solal JF, Fournier EM, Camilleri-Broet S, Spatz A, Chouaib S, et al. Selective expression of inhibitory Fcgamma receptor by metastatic melanoma impairs tumor susceptibility to IgG-dependent cellular response. Int J Cancer. (2008) 123:2832-9. doi: 10.1002/ijc.23870
183. Gul N, van Egmond M. Antibody-dependent phagocytosis of tumor cells by macrophages: a potent effector mechanism of monoclonal antibody therapy of cancer. Cancer Res. (2015) 75:5008-13. doi: 10.1158/0008-5472.CAN-15-1330
184. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol. (2003) 21:3940-7. doi: 10.1200/JCO.2003.05.013
185. Bibeau F, Lopez-Crapez E, Di Fiore F, Thezenas S, Ychou M, Blanchard F, et al. Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol. (2009) 27:1122-9. doi: 10.1200/JCO.2008.18.0463
186. Vaughan AT, Chan CH, Klein C, Glennie MJ, Beers SA, Cragg MS. Activatory and inhibitory Fcgamma receptors augment rituximab-mediated internalization of CD20 independent of signaling via the cytoplasmic domain. J Biol Chem. (2015) 290:5424-37. doi: 10.1074/jbc.M114.593806
187. Pietersz GA, Mottram PL, van de Velde NC, Sardjono CT, Esparon S, Ramsland PA, et al. Inhibition of destructive autoimmune arthritis in FcgammaRIIa transgenic mice by small chemical entities. Immunol Cell Biol. (2009) 87:3-12. doi: 10.1038/icb.2008.82
188. Boonyarattanakalin S, Martin SE, Sun Q, Peterson BR. A synthetic mimic of human Fc receptors: defined chemical modification of cell surfaces enables efficient endocytic uptake of human immunoglobulin-G. J Am Chem Soc. (2006) 128:11463-70. doi: 10.1021/ja062377w
189. Belostocki K, Park MS, Redecha PB, Masuda E, Salmon JE, Pricop L. FcgammaRIIa is a target for modulation by TNFalpha in human neutrophils. Clin Immunol. (2005) 117:78-86. doi: 10.1016/j.clim.2005.07.001
190. Chu SY, Yeter K, Kotha R, Pong E, Miranda Y, Phung S, et al. Suppression of rheumatoid arthritis B cells by XmAb5871, an anti-CD19 antibody that coengages B cell antigen receptor complex and Fcgamma receptor IIb inhibitory receptor. Arthritis Rheumatol. (2014) 66:1153-64. doi: 10.1002/art.38334
191. Horton HM, Chu SY, Ortiz EC, Pong E, Cemerski S, Leung IW, et al. Antibody-mediated coengagement of FcgammaRIIb and B cell receptor complex suppresses humoral immunity in systemic lupus erythematosus. J Immunol. (2011) 186:4223-33. doi: 10.4049/jimmunol.1003412
192. Ellsworth JL, Hamacher N, Harder B, Bannink K, Bukowski TR, Byrnes-Blake K, et al. Recombinant soluble human FcgammaR1A (CD64A) reduces inflammation in murine collagen-induced arthritis. J Immunol. (2009) 182:7272-9. doi: 10.4049/jimmunol.0803497
193. Magnusson SE, Andren M, Nilsson KE, Sondermann P, Jacob U, Kleinau S. Amelioration of collagen-induced arthritis by human recombinant soluble FcgammaRIIb. Clin Immunol. (2008) 127:225-33. doi: 10.1016/j.clim.2008.02.002
194. Konstaninova TS, Leonidovna IV, Hellmann A, Kyrcz-Krzemien S, Tillmanns S, Sondermann P, et al. Interim results from a phase Ib/IIa clinical trial with the soluble Fc-gamma IIb receptor SM101 for the treatment of primary immune thrombocytopenia. Blood. (2012) 120:3388.
195. Tillmanns S, Kolligs C, D'Cruz DP, Doria A, Hachulla E, Voll RE, et al. SM101, a novel recombinant, soluble, human FcgIIB receptor, in the treatment of systemic lupus erythematosus: results of a doubleblind, placebo-controlled multicenter study. Am Coll Rheumatol. (2014) 66:S1238.